CHRONIC MYELOMONOCYTIC LEUKEMIA

This study tests a new experimental drug called EP0042, alone or with other cancer treatments, in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The main goal is to find a safe dose that might work against the cancer. About 70 people will take part in…

This study tests a low-dose weekly combination of two FDA-approved drugs, decitabine and venetoclax, for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler schedule can control the disease while causing fewer treatment delays or interrupti…

This early-stage trial tests a pill called olutasidenib in people with certain blood cancers (AML, MDS, or CMML) who have an IDH1 gene change. The goal is to see if taking this drug after a donor stem cell transplant is safe and can help prevent the cancer from coming back. About…

This study tests a pill called olutasidenib in people with certain early blood disorders (CCUS, lower-risk MDS, or CMML) that have a specific gene change (IDH1 mutation). The goal is to see if the drug can control the disease and improve blood counts. Fifteen participants will re…

This study tests whether adding the experimental drug IMM01 to standard chemotherapy (azacitidine) helps adults newly diagnosed with chronic myelomonocytic leukemia (CMML). About 170 participants will receive either the combo or a placebo plus chemo. The main goals are complete r…

This study tests whether adding olutasidenib to standard chemotherapy can help control certain blood cancers (MDS, CMML, or MPN) in people with an IDH1 gene mutation. About 45 adults will receive the drug combination, and researchers will monitor side effects and how well the dis…

This study tests three different drug combinations to prevent graft-versus-host disease (GVHD) in 400 people with blood cancers receiving stem cells from unrelated donors. GVHD is a serious complication where donor cells attack the patient's body. The goal is to find which approa…

This study tests a new antibody drug (axatilimab) with or without a chemotherapy-like drug (azacitidine) in people with advanced blood cancers like MPN, MPN/MDS overlap, or high-risk CMML. The goal is to find the best dose and see if the combination can shrink or control the canc…

This study tests a combination of two drugs, enasidenib and azacitidine, in people with a rare, high-risk blood cancer called IDH2-mutant myelodysplastic syndrome. The goal is to see if the treatment can control the disease and reduce side effects. About 63 participants will take…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This early-stage study tests a new drug called STX-0712 in people with advanced types of leukemia (CMML or AML) that have not responded to other treatments. The main goals are to find a safe dose and check for side effects. About 105 adults will take part in this first-in-human t…

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This study tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their cancer coming back. About 324 adults aged 18 to 70 will receiv…

This study tests adding the drug momelotinib to standard treatment for people with certain rare blood cancers (MDS/MPN and chronic neutrophilic leukemia). The goal is to better control the disease, improve symptoms, and help more patients become eligible for a transplant. About 1…

This study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …

This study tests a combination of two drugs (enasidenib and azacitidine) in about 50 people with a specific genetic mutation (IDH2) and acute myeloid leukemia that has returned or not responded to prior therapy. The goal is to see if the combination can stop cancer cell growth an…

This early-phase study tests whether adding an experimental drug called defactinib to an approved oral treatment (decitabine/cedazuridine) is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonocytic leukem…

This study tests a treatment plan for adults aged 60 and older with newly diagnosed, high-risk acute myeloid leukemia (AML) or similar blood cancers. The approach combines strong chemotherapy (FLAG-Ida) with a donor stem cell transplant given just days later, using lower-intensit…

This early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…

This study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The drug blocks a protein involved in inflammation that may help cancer grow. The goal is to see if it improves blood cou…

This phase 2 trial tests whether adding high-dose vitamin C to standard chemotherapy can improve outcomes for people with lymphoma that has returned or not responded to treatment, as well as for those with related blood disorders like chronic myelomonocytic leukemia. About 80 adu…

This early-stage trial tests a new treatment for chronic myelomonocytic leukemia (CMML) that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main goals are to find a safe dose and …

This study tests an oral drug (ASTX030) that combines two chemotherapy agents to treat certain blood cancers like myelodysplastic syndromes and acute myeloid leukemia. It aims to see if taking a pill is as effective as getting injections. About 316 adults will participate over ro…

This study tests a combination of three drugs (cyclophosphamide, tacrolimus, and ruxolitinib) given after a stem cell transplant to prevent a serious complication called graft-versus-host disease (GVHD), where donor cells attack the patient's body. The trial involves 124 adults w…

This study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…

This study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple mye…

This study looks at whether certain proteins in the blood (called cytokines) can help predict how well patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or chronic myelomonocytic leukemia will do on a milder type of chemotherapy (azacytidine). Researchers …